FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* MODUR VIJAY					2. Issuer Name and Ticker or Trading Symbol Eloxx Pharmaceuticals, Inc. [ELOX]							(Che	ck all application	able)	rson(s) to Issu 10% Ov Other (s	vner	
(Last) (First) (Middle) C/O ELOXX PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 05/18/2021								X Officer (give fille Offier (specify below) HEAD OF R&D				
950 WINTER STREET				4	If Amendment, Date of Original Filed (Month/Day/Year)						6. In	6. Individual or Joint/Group Filing (Check Applicable					
(Street)	AM M	ΙA	02451		Line) X Form filed by One Form filed by More						ed by More th						
(City)	(S	tate)	(Zip)										Person				
		Та	ble I - Non-	Derivat	ive S	ecuritie	s Acc	quired, C	Dispo	sed o	f, or Be	neficially	Owned				
Date				2. Transact Date Month/Day	Execution D		Date,	Transaction Dispose Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amoun Securities Beneficia Owned Fo	s For ally (D) following (I) (m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	V A	Amount (A) or (D)			Transacti (Instr. 3 a	on(s)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	tercise (Month/Day/Year) of vative	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction Code (Instr.		e	6. Date Exercisable Expiration Date (Month/Day/Year)		e and	7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable		oiration e	Title	Amount or Number of Shares		(Instr. 4)	<u>'</u>		
Stock Options (Right to Buy)	\$1.41	05/18/2021		A		496,204		(1)	04/0	01/2031	Common Stock	496,204	\$0	496,204	D		

1. The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan in accordance with the anti-dilution provisions of the Reporting Person's employment agreement in connection with a Qualifying Financing as defined therein. The stock options vest and become exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter, subject to Reporting Person's continued employment or other service with the Issuer on each applicable vesting date, which vesting may be accelerated in connection with certain qualifying terminations of employment or in connection with a corporate transaction.

/s/ Neil S. Belloff, Attorney-in-

Fact

** Signature of Reporting Person

Date

05/18/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.